The distribution of local star formation activity as a function of galaxy stellar mass, environment and morphology

This article has been accepted for publication in Monthly Notices of the Royal Astronomical Society © 2017 The Author(s). Published by Oxford University Press on behalf of the Royal Astronomical Society. All rights reserved.We present a detailed inventory of star formation in the local Universe, dissecting the cosmic star formation budget as a function of key variables that influence the star formation rate (SFR) of galaxies: stellar mass, local environment and morphology. We use a large homogeneous dataset from the SDSS to first study how the star-formation budget in galaxies with stellar masses greater than log(M/MSun) = 10 splits as a function of each parameter separately. We then explore how the budget behaves as a simultaneous function of these three parameters. We show that the bulk of the star formation at z < 0.075 (~65 per cent) takes place in spiral galaxies, that reside in the field, and have stellar masses between 10 < log(M/MSun) < 10.9. The ratio of the cosmic star formation budget hosted by galaxies in the field, groups and clusters is 21:3:1. Morphological ellipticals are minority contributors to local star formation. They make a measurable contribution to the star formation budget only at intermediate to high stellar masses, 10.3 < log(M/MSun) < 11.2 (where they begin to dominate by number), and typically in the field, where they contribute up to ~13 per cent of the total star-formation budget. This inventory of local star formation serves as a z~0 baseline which, when combined with similar work at high redshift, will enable us to understand the changes in SFR that have occurred over cosmic time and offers a strong constraint on models of galaxy formation.Peer reviewe

Image lag optimisation in a 4T CMOS image sensor for the JANUS camera on ESA's JUICE mission to Jupiter

The CIS115, the imager selected for the JANUS camera on ESA’s JUICE mission to Jupiter, is a Four Transistor (4T) CMOS Image Sensor (CIS) fabricated in a 0.18 µm process. 4T CIS (like the CIS115) transfer photo generated charge collected in the pinned photodiode (PPD) to the sense node (SN) through the Transfer Gate (TG). These regions are held at different potentials and charge is transferred from the potential well under PPD to the potential well under the FD through a voltage pulse applied to the TG. Incomplete transfer of this charge can result in image lag, where signal in previous frames can manifest itself in subsequent frames, often appearing as ghosted images in successive readouts. This can seriously affect image quality in scientific instruments and must be minimised. This is important in the JANUS camera, where image quality is essential to help JUICE meet its scientific objectives. This paper presents two techniques to minimise image lag within the CIS115. An analysis of the optimal voltage for the transfer gate voltage is detailed where optimisation of this TG “ON” voltage has shown to minimise image lag in both an engineering model and gamma and proton irradiated devices. Secondly, a new readout method of the CIS115 is described, where following standard image integration, the PPD is biased to the reset voltage level (VRESET) through the transfer gate to empty charge on the PPD and has shown to reduce image lag in the CIS115

Predicting the effect of radiation damage on dark current in a space-qualified high performance CMOS image sensor

The CIS115 is a Teledyne-e2v CMOS image sensor with 1504 × 2000 pixels of 7 μm pitch. It has a high optical quantum efficiency owing to a multi-layer anti-reflective coating and its backside illuminated construction, and low dark current due to its pinned photodiode 4T pixel architecture. The sensor operates in rolling shutter mode with a frame rate of up to 7.5 fps (if using the whole array), and has a low readout noise of ~5 electrons rms. The CIS115 has been selected for use within the JANUS instrument, which is a high resolution camera due to launch on board ESA's JUpiter ICy moons Explorer (JUICE) spacecraft in 2022. After an interplanetary transit time of over 7 years, JUICE will spend 3.5 years touring the Jovian system, studying three of the Galilean moons in particular: Ganymede, Callisto and Europa. During this latter part of the mission, the spacecraft and hence the CIS115 sensor will be subjected to the significant levels of trapped radiation surrounding Jupiter. Gamma and proton irradiation campaigns have therefore been undertaken in order to evaluate both ionising and non-ionising dose effects on the CIS115's dark current performance. Characterisations were carried out at expected mission operating temperatures (−35 ± 10oC) both prior to and post-irradiation. Models of the resulting degradation in dark current behaviour will be combined with expected doses during the JUICE mission in order to predict the performance of the CIS115 at the mission end-of-lif

Thermal annealing response following irradiation of a CMOS imager for the JUICE JANUS instrument

ESA's JUICE (JUpiter ICy moon Explorer) spacecraft is an L-class mission destined for the Jovian system in 2030. Its primary goals are to investigate the conditions for planetary formation and the emergence of life, and how does the solar system work. The JANUS camera, an instrument on JUICE, uses a 4T back illuminated CMOS image sensor, the CIS115 designed by Teledyne e2v. JANUS imager test campaigns are studying the CIS115 following exposure to gammas, protons, electrons and heavy ions, simulating the harsh radiation environment present in the Jovian system. The degradation of 4T CMOS device performance following proton fluences is being studied, as well as the effectiveness of thermal annealing to reverse radiation damage. One key parameter for the JANUS mission is the Dark current of the CIS115, which has been shown to degrade in previous radiation campaigns. A thermal anneal of the CIS115 has been used to accelerate any annealing following the irradiation as well as to study the evolution of any performance characteristics. CIS115s have been irradiated to double the expected End of Life (EOL) levels for displacement damage radiation (2×1010 protons, 10 MeV equivalent). Following this, devices have undergone a thermal anneal cycle at 100°C for 168 hours to reveal the extent to which CIS115 recovers pre-irradiation performance. Dark current activation energy analysis following proton fluence gives information on trap species present in the device and how effective anneal is at removing these trap species. Thermal anneal shows no quantifiable change in the activation energy of the dark current following irradiation

A catalogue of faint local radio AGN and the properties of their host galaxies

This article has been accepted for publication in Monthly Notices of the Royal Astronomical Society. ©: 2018 The Author(s). Published by Oxford University Press on behalf of the Royal Astronomical Society. All rights reserved.We present a catalogue of 2210 local ( z < 0.1) galaxies that contain faint active galactic nuclei (AGN). We select these objects by identifying galaxies that exhibit a significant excess in their radio luminosities, compared to what is expected from the observed levels of star formation activity in these systems. This is achieved by comparing the optical (spectroscopic) star formation rate (SFR) to the 1.4 GHz luminosity measured from the Faint Images of the Radio Sky at Twenty centimeters survey. The majority of the AGN identified in this study are fainter than those in previous work, such as in the Best and Heckman (2012) catalogue. We show that these faint AGN make a non-negligible contribution to the radio luminosity function at low luminosities (below 1022.5 W Hz−1), and host ∼13 per cent of the local radio luminosity budget. Their host galaxies are predominantly high stellar-mass systems (with a median stellar mass of 1011 M⊙), are found across a range of environments (but typically in denser environments than star-forming galaxies) and have early-type morphologies. This study demonstrates a general technique to identify AGN in galaxy populations where reliable optical SFRs can be extracted using spectro-photometry and where radio data are also available so that a radio excess can be measured. Our results also demonstrate that it is unsafe to infer SFRs from radio emission alone, even if bright AGN have been excluded from a sample, since there is a significant population of faint radio AGN that may contaminate the radio-derived SFRs.Peer reviewedFinal Published versio

Comparing the immune response to a novel intranasal nanoparticle PLGA vaccine and a commercial BPI3V vaccine in dairy calves

peer-reviewedBackground There is a need to improve vaccination against respiratory pathogens in calves by stimulation of local immunity at the site of pathogen entry at an early stage in life. Ideally such a vaccine preparation would not be inhibited by the maternally derived antibodies. Additionally, localized immune response at the site of infection is also crucial to control infection at the site of entry of virus. The present study investigated the response to an intranasal bovine parainfluenza 3 virus (BPI3V) antigen preparation encapsulated in PLGA (poly dl-lactic-co-glycolide) nanoparticles in the presence of pre-existing anti-BPI3V antibodies in young calves and comparing it to a commercially available BPI3V respiratory vaccine. Results There was a significant (P < 0.05) increase in BPI3V-specific IgA in the nasal mucus of the BPI3V nanoparticle vaccine group alone. Following administration of the nanoparticle vaccine an early immune response was induced that continued to grow until the end of study and was not observed in the other treatment groups. Virus specific serum IgG response to both the nanoparticle vaccine and commercial live attenuated vaccine showed a significant (P < 0.05) rise over the period of study. However, the cell mediated immune response observed didn’t show any significant rise in any of the treatment groups. Conclusion Calves administered the intranasal nanoparticle vaccine induced significantly greater mucosal IgA responses, compared to the other treatment groups. This suggests an enhanced, sustained mucosal-based immunological response to the BPI3V nanoparticle vaccine in the face of pre-existing antibodies to BPI3V, which are encouraging and potentially useful characteristics of a candidate vaccine. However, ability of nanoparticle vaccine in eliciting cell mediated immune response needs further investigation. More sustained local mucosal immunity induced by nanoparticle vaccine has obvious potential if it translates into enhanced protective immunity in the face of virus outbreak

The spatially resolved star formation history of mergers: A comparative study of the LIRGs IC 1623, NGC 6090, NGC 2623, and Mice

This paper presents the spatially resolved star formation history (2D-SFH) of a small sample of four local mergers: the early-stage mergers IC 1623, NGC 6090, and the Mice, and the more advanced merger NGC 2623, by analyzing IFS data from the CALIFA survey and PMAS in LArr mode. Full spectral fitting techniques are applied to the datacubes to obtain the spatially resolved mass growth histories, the time evolution of the star formation rate intensity (Σ SFR ), and the local specific star formation rate (sSFR), over three different time scales (30 Myr, 300 Myr, and 1 Gyr). The results are compared with non-interacting Sbc-Sc galaxies, to quantify if there is an enhancement of the star formation and to trace its time scale and spatial extent. Our results for the three LIRGs (IC 1623 W, NGC 6090, and NGC 2623) show that a major phase of star formation is occurring in time scales of 10 7 yr to few 10 8 yr, with global SFR enhancements of between approximately two and six with respect to main-sequence star forming (MSSF) galaxies. In the two early-stage mergers IC 1623 W and NGC 6090, which are between first pericentre passage and coalescence, the most remarkable increase of the SFR with respect to non-interacting spirals occurred in the last 30 Myr, and it is spatially extended, with enhancements of factors between two and seven both in the centres (r 1 HLR). In the more advanced merger NGC 2623 an extended phase of star formation occurred on a longer time scale of ∼1 Gyr, with a SFR enhancement of a factor of approximately two-to-three larger than the one in Sbc-Sc MSSF galaxies over the same period, probably relic of the first pericentre passage epoch. A SFR enhancement in the last 30 Myr is also present, but only in NGC 2623 centre, by a factor of three. In general, the spatially resolved SFHs of the LIRG-mergers are consistent with the predictions from high spatial resolution simulations. In contrast, the star formation in the Mice, specially in Mice B, is not enhanced but inhibited with respect to Sbc-Sc MSSF galaxies. The fact that the gas fraction of Mice B is smaller than in most non-interacting spirals, and that the Mice are close to a prograde orbit, represents a new challenge for the models, which must cover a larger space of parameters in terms of the availability of gas and the orbital characteristics

Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Dimethyl fumarate (DMF) inhibits inflammasome-mediated inflammation and has been proposed as a treatment for patients hospitalised with COVID-19. This randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple treatments in patients hospitalised for COVID-19 (NCT04381936, ISRCTN50189673). In this assessment of DMF performed at 27 UK hospitals, adults were randomly allocated (1:1) to either usual standard of care alone or usual standard of care plus DMF. The primary outcome was clinical status on day 5 measured on a seven-point ordinal scale. Secondary outcomes were time to sustained improvement in clinical status, time to discharge, day 5 peripheral blood oxygenation, day 5 C-reactive protein, and improvement in day 10 clinical status. Between 2 March 2021 and 18 November 2021, 713 patients were enroled in the DMF evaluation, of whom 356 were randomly allocated to receive usual care plus DMF, and 357 to usual care alone. 95% of patients received corticosteroids as part of routine care. There was no evidence of a beneficial effect of DMF on clinical status at day 5 (common odds ratio of unfavourable outcome 1.12; 95% CI 0.86-1.47; p = 0.40). There was no significant effect of DMF on any secondary outcome

Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Dimethyl fumarate (DMF) inhibits inflammasome-mediated inflammation and has been proposed as a treatment for patients hospitalised with COVID-19. This randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple treatments in patients hospitalised for COVID-19 (NCT04381936, ISRCTN50189673). In this assessment of DMF performed at 27 UK hospitals, adults were randomly allocated (1:1) to either usual standard of care alone or usual standard of care plus DMF. The primary outcome was clinical status on day 5 measured on a seven-point ordinal scale. Secondary outcomes were time to sustained improvement in clinical status, time to discharge, day 5 peripheral blood oxygenation, day 5 C-reactive protein, and improvement in day 10 clinical status. Between 2 March 2021 and 18 November 2021, 713 patients were enroled in the DMF evaluation, of whom 356 were randomly allocated to receive usual care plus DMF, and 357 to usual care alone. 95% of patients received corticosteroids as part of routine care. There was no evidence of a beneficial effect of DMF on clinical status at day 5 (common odds ratio of unfavourable outcome 1.12; 95% CI 0.86-1.47; p = 0.40). There was no significant effect of DMF on any secondary outcome